CalciMedica (CALC) Competitors $3.20 +0.15 (+4.92%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.22 +0.01 (+0.47%) As of 10/3/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CALC vs. MIST, SLS, TARA, AVTX, NLTX, MCRB, CTOR, GNLX, CLLS, and CCCCShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Milestone Pharmaceuticals (MIST), SELLAS Life Sciences Group (SLS), Protara Therapeutics (TARA), Avalo Therapeutics (AVTX), Neoleukin Therapeutics (NLTX), Seres Therapeutics (MCRB), Citius Oncology (CTOR), Genelux (GNLX), Cellectis (CLLS), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Its Competitors Milestone Pharmaceuticals SELLAS Life Sciences Group Protara Therapeutics Avalo Therapeutics Neoleukin Therapeutics Seres Therapeutics Citius Oncology Genelux Cellectis C4 Therapeutics Milestone Pharmaceuticals (NASDAQ:MIST) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Do institutionals and insiders believe in MIST or CALC? 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 41.6% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor MIST or CALC? In the previous week, Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled CalciMedica'saverage media sentiment score. Company Overall Sentiment Milestone Pharmaceuticals Neutral CalciMedica Neutral Which has better earnings and valuation, MIST or CALC? CalciMedica has lower revenue, but higher earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Pharmaceuticals$1M179.33-$41.52M-$0.84-2.51CalciMedicaN/AN/A-$13.70M-$1.60-2.00 Do analysts rate MIST or CALC? Milestone Pharmaceuticals currently has a consensus target price of $4.50, indicating a potential upside of 113.27%. CalciMedica has a consensus target price of $16.00, indicating a potential upside of 400.00%. Given CalciMedica's higher probable upside, analysts clearly believe CalciMedica is more favorable than Milestone Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17CalciMedica 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is MIST or CALC more profitable? CalciMedica's return on equity of -206.51% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Milestone PharmaceuticalsN/A -1,672.29% -83.09% CalciMedica N/A -206.51%-103.81% Which has more volatility and risk, MIST or CALC? Milestone Pharmaceuticals has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. SummaryMilestone Pharmaceuticals and CalciMedica tied by winning 6 of the 12 factors compared between the two stocks. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.71M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.67%4.69%P/E Ratio-2.0022.2886.9626.71Price / SalesN/A458.33605.32131.81Price / CashN/A47.8637.9061.31Price / Book2.999.9312.556.55Net Income-$13.70M-$52.80M$3.31B$277.50M7 Day Performance3.90%5.22%4.28%2.42%1 Month Performance3.90%10.61%6.90%8.63%1 Year Performance-26.58%25.03%70.54%31.60% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica2.2754 of 5 stars$3.20+4.9%$16.00+400.0%-26.6%$44.71MN/A-2.0030MISTMilestone Pharmaceuticals1.8172 of 5 stars$2.00-1.5%$4.50+125.0%+40.7%$169.98M$1M-2.3830Positive NewsSLSSELLAS Life Sciences Group2.2431 of 5 stars$1.61+3.2%$7.00+334.8%+48.4%$169.53M$1M-5.0310News CoveragePositive NewsShort Interest ↓TARAProtara Therapeutics1.5494 of 5 stars$4.35-1.4%$19.60+350.6%+177.1%$167.82MN/A-2.6930Gap UpAVTXAvalo Therapeutics3.2923 of 5 stars$12.71-2.4%$31.67+149.1%+37.2%$167.16M$441K0.0040Short Interest ↑High Trading VolumeNLTXNeoleukin TherapeuticsN/A$17.71-0.6%N/A-54.0%$166.44MN/A-5.6990High Trading VolumeMCRBSeres Therapeutics2.4313 of 5 stars$19.24+2.9%$14.33-25.5%+21.3%$163.62MN/A-4.18330Positive NewsCTORCitius Oncology3.2306 of 5 stars$2.03flat$6.00+195.6%+58.8%$159.09MN/A0.00N/AShort Interest ↓Gap DownGNLXGenelux1.6137 of 5 stars$4.20-1.2%$20.33+384.1%+76.6%$158.65MN/A-4.8810News CoveragePositive NewsCLLSCellectis1.7773 of 5 stars$2.85+0.4%$4.00+40.4%+84.8%$158.40M$49.22M-3.48290Positive NewsCCCCC4 Therapeutics3.7278 of 5 stars$2.22-0.4%$8.50+282.9%-57.8%$158.00M$35.58M-1.41150Positive News Related Companies and Tools Related Companies Milestone Pharmaceuticals Alternatives SELLAS Life Sciences Group Alternatives Protara Therapeutics Alternatives Avalo Therapeutics Alternatives Neoleukin Therapeutics Alternatives Seres Therapeutics Alternatives Citius Oncology Alternatives Genelux Alternatives Cellectis Alternatives C4 Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALC) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.